BAY-8400

Cat. No.:	HY-132293
CAS No.:	2763602-59-9
Molecular Formula:	$C_{21}H_{17}F_2N_5O$
Molecular Weight:	393.39
Target:	DNA-PK
Pathway:	Cell Cycle/DNA Damage; PI3K/Akt/mTOR
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 62.5 mg/mL (158.88 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	2.5420 mL	12.7100 mL	25.4201 mL
5 mM	0.5084 mL	2.5420 mL	5.0840 mL
10 mM	0.2542 mL	1.2710 mL	2.5420 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.08 mg/mL (5.29 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

BAY-8400 is an orally active, potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (IC_{50}=81 nM). BAY-8400 can be used for the research of cancer[1].

IC_{50} & Target

IC50: 81 nM (DNA-PK)[1]

In Vivo

BAY-8400 (150 mg/kg; p.o.) increases the antitumor efficacy. BAY-8400 shows useful aqueoussolubility and oral bioavailability across species[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Nat Biotechnol. 2023 Aug 3.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Berger M, et al. BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies [published online ahead of print, 2021 Aug 24]. J Med Chem. 2021;10.1021/acs.jmedchem.1c00762.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA